Success Metrics

Clinical Success Rate
89.7%

Based on 26 completed trials

Completion Rate
90%(26/29)
Active Trials
0(0%)
Results Posted
23%(6 trials)
Terminated
3(10%)

Phase Distribution

Ph phase_3
1
3%
Ph phase_1
19
63%
Ph phase_2
10
33%

Phase Distribution

19

Early Stage

10

Mid Stage

1

Late Stage

Phase Distribution30 total trials
Phase 1Safety & dosage
19(63.3%)
Phase 2Efficacy & side effects
10(33.3%)
Phase 3Large-scale testing
1(3.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

86.7%

26 of 30 finished

Non-Completion Rate

13.3%

4 ended early

Currently Active

0

trials recruiting

Total Trials

30

all time

Status Distribution
Completed(26)
Terminated(4)

Detailed Status

Completed26
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
30
Active
0
Success Rate
89.7%
Most Advanced
Phase 3

Trials by Phase

Phase 119 (63.3%)
Phase 210 (33.3%)
Phase 31 (3.3%)

Trials by Status

withdrawn13%
terminated310%
completed2687%

Recent Activity

0 active trials
Showing 5 of 30
completedphase_1

Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)

NCT00694083
completedphase_2

Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer

NCT00770185
completedphase_1

Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT01169532
terminatedphase_1

Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer

NCT01212627
completedphase_1

Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)

NCT01380184
View all 30 trials

Clinical Trials (30)

Showing 20 of 30 trialsScroll for more
NCT00694083Phase 1

Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)

Completed
NCT00770185Phase 2

Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer

Completed
NCT01169532Phase 1

Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

Completed
NCT01212627Phase 1

Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer

Terminated
NCT01380184Phase 1

Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)

Completed
NCT01605396Phase 2

A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)

Completed
NCT01431534Phase 1

A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)

Terminated
NCT01243762Phase 1

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Terminated
NCT01256268Phase 1

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Completed
NCT01234857Phase 2

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)

Completed
NCT01431547Phase 1

Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Completed
NCT00110188Phase 2

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Completed
NCT01295632Phase 1

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Completed
NCT00060645Phase 1

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Completed
NCT00060632Phase 1

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Completed
NCT00736970Phase 2

Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

Completed
NCT00086125Phase 2

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Completed
NCT00288431Phase 1

Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

Completed
NCT00739830Phase 2

Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)

Completed
NCT01010672Phase 2

Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
30